Spring Builders: steven rios

Custom Services and Assay Kits for Detecting Cytokines with Homogeneous Luminescence Assay

steven rios — Tue, 21 Jul 2026 09:36:19 +0000

Cytokines are a class of small-molecule proteins that are secreted by cells. They include interleukins, interferons, tumour necrosis factors, growth factors and chemokines. They bind to corresponding receptors on effector cells, thereby initiating signal transduction. Cytokines are well-established to play a key role in immune responses such as infection, inflammation, haematopoiesis, maintenance of homeostasis, tissue repair, cell development, growth and tumorigenesis. Dysfunction or dysregulation of cytokines has been associated with a wide range of diseases.

Cytokines can be used to characterize pathological conditions, infections or injuries, and they can even be employed to assess disease progression. Consequently, cytokine detection is of significant importance in basic immunological research, exploring disease mechanisms, diagnosing diseases, developing vaccines and cell therapy. One of the most commonly used methods is the ELISA. However, this method is cumbersome, time-consuming and susceptible to various factors.

To overcome these limitations, CD Bioparticles has developed a series of homogeneous luminescent cytokine detection kits. This technology significantly simplifies operational workflows, reducing labour and time costs while enabling the rapid, accurate, quantitative detection of cytokines in cell culture supernatants or serum samples. CD Bioparticles offers development and testing services for homogeneous luminescent cytokine assay kits to meet the diverse needs of researchers.

Compared to ELISA, homogeneous luminescence assays offer several advantages for cytokine detection. For example, there is no need for repeated washing steps: samples simply need to be added and incubated prior to testing. Results are obtained more rapidly with higher throughput, making the method better suited to automated processes. Furthermore, they offer higher sensitivity and a wider dynamic range whilst presenting a lower risk of interference. They also require smaller sample volumes and offer greater sample compatibility, making them suitable for natural samples such as cell culture supernatants and serum.

CD Bioparticles offers custom services to assist researchers in detecting various cytokines using homogeneous luminescence technology. These services cover every stage, from sample testing and custom conjugation to developing complete homogeneous luminescence assay methods. They include cytokine detection services, development of homogeneous luminescence assay kits, custom conjugation of antibodies/antigens with ligands and receptors, and assay validation.

For more information regarding CD Bioparticles' services for detecting cytokines with homogeneous luminescence assay or to discuss custom study protocols, please visit the official service platform at https://www.cd-bioparticles.com/services/detecting-cytokines-with-homogeneous-luminescence-assay.html.

About CD Bioparticles

CD Bioparticles is a leading manufacturer and supplier of various nanoparticles, microparticles, and coatings for R&D as well as commercialization across different application areas, including in vitro diagnostics, biochemistry, cellular analysis, cell separation, and immunoassay. The company also offers various custom services, including chemical surface-functionalization, fluorescent modification, antibody immobilization, as well as nucleic acid and oligo conjugation to meet client specifications.

Advanced Microneedle Device Customization Services to Accelerate Transdermal Drug Delivery Innovation

steven rios — Tue, 21 Jul 2026 09:35:14 +0000

Microneedles (MNs) are micrometre-scale needles that range in height from 25 to 2,000 micrometres. They are manufactured from a variety of materials and are available in a range of shapes. Microneedle technology is a recent advancement in biomedical science. MN-based drug delivery technology can overcome many of the limitations currently faced in drug delivery, including low absorption rates, low bioavailability, insufficient skin permeability and poor biodistribution.

Nanotechnology has significantly transformed microneedle manufacturing processes, shifting from traditional to innovative designs and incorporating various natural and synthetic materials, as well as combinations thereof. Due to its multifaceted and extensive application prospects, microneedle technology has gained widespread popularity in the fields of global biomedical research and drug delivery technology.

CD Bioparticles now offers customized microneedle manufacturing equipment and modular production systems to support the entire development process, from early-stage research to pilot-scale production. The company's solutions include laboratory-scale experimental systems (bench-top equipment) for formulation screening and process development, as well as pilot-scale production systems for process validation and small-batch manufacturing.

CD Bioparticles' microneedle equipment is built on industrial-grade, high-frequency, impact-jet fluid control technology, and is specifically designed for the precise filling of microneedle tips and coating of substrate materials. The system ensures stable and accurate fluid delivery through the coordinated operation of high-precision core modules.

In addition, all components support modularity and flexible customization, including adjustable micro-nozzles and liquid reservoirs of various sizes. The system is fully compatible with a wide range of high-viscosity polymer formulations, including PVP, PVA, HA and PLGA, and is suitable for various microneedle array designs.

The custom development process comprises four steps, including 1)requirement evaluation (microneedle product evaluation and manufacturing process analysis); 2) engineering design & system development; 3) equipment manufacturing (machining of core components, automation system integration, software control system integration, and internal mechanical calibration); 4) delivery & technical support (on-site installation and commissioning of microneedle equipment, operator training, and remote technical support for up to one year).

CD Bioparticles' microneedle manufacturing systems are widely used for cosmetic microneedle patches, vaccines, exosome delivery systems, peptide delivery platforms, transdermal drug delivery, biologics development, aesthetic skincare products, and medical device manufacturing. CD Bioparticles assists clients in establishing stable, reproducible and scalable microneedle manufacturing platforms to meet their diverse application requirements, from prototype development to pilot production.

For more details regarding CD Bioparticles' Microneedle Device Customization Services or to request technical specifications for available micro-fabrication platforms, please visit https://www.cd-bioparticles.net/services/microneedle-device-customization-services.html.

About CD Bioparticles

CD Bioparticles is an established drug delivery company that provides customized solutions for developing and manufacturing novel biocompatible drug delivery systems. It specializes in various formulation and drug delivery technologies, from conventional liposomes and PEGylated liposomes to polymer microspheres and nanoparticles for drug delivery. The company also provides contract research services for drug delivery formulation, formulation feasibility study, process development and scale-up, as well as analytical and non-clinical research services.

Services for Colloidal Gold Lateral Flow Assays to Accelerate Point-of-Care Diagnostics

steven rios — Tue, 26 May 2026 05:09:12 +0000

LFA is a paper-based platform used to detect and quantify analytes in complex mixtures. The procedure involves placing a sample on the test device and obtaining results within 5 to 30 minutes. Depending on the recognition element used, LFAs can be broadly classified into two categories. Lateral flow immunoassays are utilized as recognition elements. Nucleic acid lateral flow assays detect amplicons that may be formed during the polymerase chain reaction (PCR) process. LFAs are inexpensive to produce and simple to operate. Importantly, they have also been widely accepted by users and regulatory authorities, making them well-suited to meeting the growing demand for point-of-care, multiplexed diagnostic testing.

Colloidal gold LFAs offer numerous advantages, such as a visible colour reaction that facilitates rapid detection and specific labelling. Furthermore, they are highly stable and suitable for large-scale production, and are also well-suited to home or on-site testing. They possess multiplexing capabilities, high sensitivity, and quantitative potential when used with dedicated equipment, eliminating the need for expensive specialized equipment.

CD Bioparticles offers custom services to assist researchers in developing colloidal gold lateral flow immunoassay products. The company's services range from customizing nanoparticle conjugates to optimizing complete LFA systems. CD Bioparticles can provide comprehensive support to clients throughout the entire process, including feasibility studies, initial development stages and the final commercialisation phase.

A dedicated technical support team is available to answer clients' queries and discuss project requirements in detail. This team provides timely progress reports at each stage and offers post-delivery assistance as required. The team has extensive experience in delivering comprehensive services covering sample preparation, critical material selection, experimental protocol design, and validation. The company is also highly skilled in optimizing running buffers, conjugation methods and nanoparticles. CD Bioparticles can help clients transfer and optimize existing proof-of-concept assays into rapid, flow cytometry-based diagnostic solutions.

Furthermore, the company has the capability to produce high-quality, low-cost nanoparticles for rapid diagnostic testing, including gold colloids, upconversion nanoparticles and quantum dots. The company can supply uniform nanoparticles with varying sizes and surface properties for LFA development. Large-scale production combined with years of stability testing enables clients to minimize production risks.

CD Bioparticles conducts comprehensive characterization analyses on all particles to ensure that every batch meets specification requirements. Strict quality control measures are implemented at every stage of the LFA development process to ensure the final product is highly accurate, reliable and consistent.

For more information about CD Bioparticles' Colloidal Gold Lateral Flow Assay development services, please visit https://www.cd-bioparticles.com/services/colloidal-gold-lateral-flow-assay-development.html.

Organoid Culture Tools to Advance 3D Disease Modeling and Drug Discovery

steven rios — Tue, 26 May 2026 02:35:55 +0000

Organoids are simple cell-based in vitro tissue engineering models that can reproduce many aspects of the complex structure and function of their corresponding in vivo tissues. They can be dissected and analyzed to study the fundamental mechanisms of human tissue development, regeneration, and repair. They can also be used for diagnostics, disease modelling, drug development, and personalized medicine. Organoids can be derived from pluripotent stem cells, tissue-resident stem cells (embryonic or adult), progenitor cells or differentiated cells from healthy or diseased tissues (such as tumors). A large number of organoid engineering strategies supporting the culture, growth, proliferation, differentiation and maturation of organoids have been reported to date.

Complex, three-dimensional organoids represent a unique research tool, offering significant advantages over overly simplified, two-dimensional cell culture systems and animal models, which often fail to accurately replicate human physiological and pathological conditions. As the scientific community moves away from traditional two-dimensional cell culture and seeks alternatives that more closely mimic the human body than animal experiments do, CD Bioparticles' organoid culture tools provide the key building blocks for constructing these 'mini-organs', thus facilitating breakthroughs in cancer research, regenerative medicine, and personalized drug screening.

The newly released product line includes Human-Derived Normal Organoid Kits, Human-Derived Tumor Organoid Kits, Mouse-Derived Normal Organoid Kits, and Organoid-Related Reagents. For example, CD Bioparticles' Tumor Organoid Kits (Human-Derived) are designed to help researchers construct three-dimensional models that closely replicate the native tumour microenvironment. The range includes kits for various common tumour types and is intended to advance cancer research by facilitating more precise and efficient experimental methods and accelerating the development of personalized cancer therapies.

CD Bioparticles' kits provide a comprehensive solution, combining tumour tissue processing, organoid culture, passaging, cryopreservation, and thawing. They support the efficient establishment of tumour organoid models using primary samples obtained from surgical resection or biopsy with excellent reproducibility and a high success rate. Thanks to optimized formulations and standardized operating procedures, the resulting organoids retain the original tumour's key characteristics, including tissue structure, genetic mutation profiles, cellular heterogeneity, and drug response profiles. These properties make the organoids an ideal choice for applications, such as personalized medicine research, anti-cancer drug screening, high-throughput drug sensitivity testing, and cancer mechanism studies.

For more information on the Organoid Culture Tools or to view the full product catalog, please visit CD Bioparticles at https://www.cd-bioparticles.net/products/organoid-culture-tools.html.